Cristina Castillo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Cristina Castillo has a total of 85 co-authors. Here are the top co-authors by number of shared publications:
- Nupur K. Das
Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, USA
12 shared publications - Yatrik M. Shah
University of Michigan
11 shared publications - Marwa Omar El-Derany
University of Michigan
10 shared publications - Andrii Balia
Department of Medicinal Chemistry, College of Pharmacy, University of Michigan, Ann Arbor, Michigan
9 shared publications - Elizabeth C. McCulla
Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan
9 shared publications - Hannah Noelle Bell
Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, Michigan
9 shared publications
Latest Publications
- Open Access
Perforin triggers iron-induced mitochondrial damage to drive ferroptosis and anti-tumor immunity
- Open Access
- 12 March 2026
- Published by Elsevier in Blood Red Cells & Iron
- Vol. 2 (2)
Identification and characterization of novel hepcidin mimetics that modulate ferroportin function
- 12 March 2026
- Published by Elsevier in Blood Red Cells & Iron
- Vol. 2 (2)
Open AccessIdentification and characterization of novel hepcidin mimetics that modulate ferroportin function
- Open Access
Intestine-Specific Ferroportin Ablation Rescues from Systemic Iron Overload in Mice
Background/Objectives: The hepcidin–ferroportin (Fpn1) axis is central to intestinal iron absorption, and dysregulation of this axis underlies all known forms of iron disorders. Hemochromatosis, the most common iron overload disorder in humans, results from systemic iron accumulation due to decades of uncontrolled intestinal absorption. Despite major advances in medicine in recent years, strategies for iron overload management are still lagging as they primarily rely on iron chelation and repeated phlebotomies. Fpn1, the cellular iron exporter, is ubiquitously expressed and plays a critical role in maintaining systemic iron homeostasis. Methods: To investigate the specific contribution of intestinal Fpn1 to systemic iron overload, we employed a CRISPR-based adenoviral hepcidin knockout mediated mouse iron overload model, combined with intestine-specific deletion of Fpn1. Results: An initial time-dependent experiment establishes the efficiency of hepcidin knockout (KO) by as early as 1 week of adenovirus injection. At 2 weeks of injection, a perfect reciprocal relationship between hepcidin gene suppression and liver iron levels (5–7-fold induction from the baseline) was established. Finally, intestine-specific Fpn1 deletion effectively prevented iron accumulation in hepcidin KO mice, as evidenced by nearly 4-fold lower liver iron levels compared to hepcidin KO animals with intact intestinal Fpn1. Conclusions: In summary, our results demonstrate that ablation of intestinal Fpn1 is sufficient to attenuate systemic iron accumulation in this mouse model of hemochromatosis. These findings suggest that selective targeting of intestinal Fpn1 may represent a promising strategy for the management of iron overload.
Open AccessIntestine-Specific Ferroportin Ablation Rescues from Systemic Iron Overload in Mice
Background/Objectives: The hepcidin–ferroportin (Fpn1) axis is central to intestinal iron absorption, and dysregulation of this axis underlies all known forms of iron disorders. Hemochromatosis, the most common iron overload disorder in humans, results from systemic iron accumulation due to decades of uncontrolled intestinal absorption. Despite major advances in medicine in recent years, strategies for iron overload management are still lagging as they primarily rely on iron chelation and repeated phlebotomies. Fpn1, the cellular iron exporter, is ubiquitously expressed and plays a critical role in maintaining systemic iron homeostasis. Methods: To investigate the specific contribution of intestinal Fpn1 to systemic iron overload, we employed a CRISPR-based adenoviral hepcidin knockout mediated mouse iron overload model, combined with intestine-specific deletion of Fpn1. Results: An initial time-dependent experiment establishes the efficiency of hepcidin knockout (KO) by as early as 1 week of adenovirus injection. At 2 weeks of injection, a perfect reciprocal relationship between hepcidin gene suppression and liver iron levels (5–7-fold induction from the baseline) was established. Finally, intestine-specific Fpn1 deletion effectively prevented iron accumulation in hepcidin KO mice, as evidenced by nearly 4-fold lower liver iron levels compared to hepcidin KO animals with intact intestinal Fpn1. Conclusions: In summary, our results demonstrate that ablation of intestinal Fpn1 is sufficient to attenuate systemic iron accumulation in this mouse model of hemochromatosis. These findings suggest that selective targeting of intestinal Fpn1 may represent a promising strategy for the management of iron overload.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from Recharacterization of the Tumor Suppressive Mechanism of RSL3 Identifies the Selenoproteome as a Druggable Pathway in Colorectal Cancer
Supplementary Figure S5 shows oxidative stress markers, apoptosis, systemic toxicity, and histological outcomes following in vivo auranofin treatments in mouse models.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Recharacterization of the Tumor Suppressive Mechanism of RSL3 Identifies the Selenoproteome as a Druggable Pathway in Colorectal Cancer
Supplementary Figure S5 shows oxidative stress markers, apoptosis, systemic toxicity, and histological outcomes following in vivo auranofin treatments in mouse models.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from Recharacterization of the Tumor Suppressive Mechanism of RSL3 Identifies the Selenoproteome as a Druggable Pathway in Colorectal Cancer
Supplementary Figure S2 validates GPX4 knockdown efficacy, details antioxidant enzyme activities under RSL3 and auranofin treatments, and includes kinetic assays for thioredoxin reductase activity in CRC cells.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Recharacterization of the Tumor Suppressive Mechanism of RSL3 Identifies the Selenoproteome as a Druggable Pathway in Colorectal Cancer
Supplementary Figure S2 validates GPX4 knockdown efficacy, details antioxidant enzyme activities under RSL3 and auranofin treatments, and includes kinetic assays for thioredoxin reductase activity in CRC cells.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S7 from Recharacterization of the Tumor Suppressive Mechanism of RSL3 Identifies the Selenoproteome as a Druggable Pathway in Colorectal Cancer
Supplementary Figure S7 shows the impact of AlkBH8 KD on GPX1/2 protein levels, CRC cell growth, colony formation, and tests the rescuing effects of sodium selenite under RSL3 and auranofin treatments.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Recharacterization of the Tumor Suppressive Mechanism of RSL3 Identifies the Selenoproteome as a Druggable Pathway in Colorectal Cancer
Supplementary Figure S7 shows the impact of AlkBH8 KD on GPX1/2 protein levels, CRC cell growth, colony formation, and tests the rescuing effects of sodium selenite under RSL3 and auranofin treatments.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from Recharacterization of the Tumor Suppressive Mechanism of RSL3 Identifies the Selenoproteome as a Druggable Pathway in Colorectal Cancer
Supplementary Figure S1 shows GPX4 stability using CETSA assays and CRC cell growth responses to RSL3 treatment, with or without Liproxstatin-1 rescue.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Recharacterization of the Tumor Suppressive Mechanism of RSL3 Identifies the Selenoproteome as a Druggable Pathway in Colorectal Cancer
Supplementary Figure S1 shows GPX4 stability using CETSA assays and CRC cell growth responses to RSL3 treatment, with or without Liproxstatin-1 rescue.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Materials and Methods from Recharacterization of the Tumor Suppressive Mechanism of RSL3 Identifies the Selenoproteome as a Druggable Pathway in Colorectal Cancer
This methods details synthetic procedures for biotinylated analogs, including reagents, conditions, and yields.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Materials and Methods from Recharacterization of the Tumor Suppressive Mechanism of RSL3 Identifies the Selenoproteome as a Druggable Pathway in Colorectal Cancer
This methods details synthetic procedures for biotinylated analogs, including reagents, conditions, and yields.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from Recharacterization of the Tumor Suppressive Mechanism of RSL3 Identifies the Selenoproteome as a Druggable Pathway in Colorectal Cancer
Supplementary Figure S6 explores the functional importance of selenoproteins in CRC via CRISPR co-essentiality analyses, qPCR validations of AlkBH8 KD, and survival analyses of tRNA-sec biosynthetic pathway genes.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Recharacterization of the Tumor Suppressive Mechanism of RSL3 Identifies the Selenoproteome as a Druggable Pathway in Colorectal Cancer
Supplementary Figure S6 explores the functional importance of selenoproteins in CRC via CRISPR co-essentiality analyses, qPCR validations of AlkBH8 KD, and survival analyses of tRNA-sec biosynthetic pathway genes.
- Open Access
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from Recharacterization of the Tumor Suppressive Mechanism of RSL3 Identifies the Selenoproteome as a Druggable Pathway in Colorectal Cancer
Supplementary Figure S4 provides CETSA data to illustrate the absence of direct GPX4 interaction with the compound auranofin in treated cells.
- 1 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Recharacterization of the Tumor Suppressive Mechanism of RSL3 Identifies the Selenoproteome as a Druggable Pathway in Colorectal Cancer
Supplementary Figure S4 provides CETSA data to illustrate the absence of direct GPX4 interaction with the compound auranofin in treated cells.